Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating ... While this disease is not cancer, its progression is similar to that of lymphoma, a cancer of the lymph nodes.

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

Sept 20 - The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ... its commitment to oncology drug development even after a ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

Sanofi agreed to pay up to 320 million euros ... bet by a major pharmaceutical company on an emerging class of cancer drugs known as radiopharmaceuticals, which use radioactive substances to ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Sanofi is following several of its big pharma ... submission as a treatment for a rare type of gastrointestinal cancer. According to deal terms announced Thursday, Sanofi is paying €100 million ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.